Lundgren, Christine http://orcid.org/0000-0002-7880-2981
Bendahl, Pär-Ola
Borg, Åke
Ehinger, Anna
Hegardt, Cecilia
Larsson, Christer
Loman, Niklas
Malmberg, Martin
Olofsson, Helena
Saal, Lao H.
Sjöblom, Tobias
Lindman, Henrik
Klintman, Marie
Häkkinen, Jari
Vallon-Christersson, Johan
Fernö, Mårten
Rydén, Lisa
Ekholm, Maria
Funding for this research was provided by:
The Swedish Breast Cancer Association
The Swedish Breast Cancer Group
Futurum – the Academy for Health and Care, Region Jönköping County
Article History
Received: 13 May 2019
Accepted: 24 July 2019
First Online: 20 August 2019
Compliance with ethical standards
:
: Author Anna Ehinger has received remuneration from Roche, Amgen and Novartis. Author Lao H. Saal has received remuneration and has stock ownership in SAGA Diagnostics AB. Author Maria Ekholm has had a consultant/advisory role in Pfizer and Novartis. The other authors declare that they have no conflict of interest.
: This study is covered by previous ethical approvals from the Ethics Board in Lund (Dnr: 2009/658, 2010/383, 2012/58, 2013/459, 2014/521, 2015/277, 2016/944). It is a prospective study, but no procedures or interventions were performed.
: Informed consent has previously been obtained from all individual participants included in the SCAN-B study.
: This article does not contain any studies with human participants or animals performed by any of the authors.